PHARMING GROUP N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.881 EUR | +1.50% |
|
-11.72% | -14.55% |
| Apr. 18 | Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds | MT |
| Apr. 18 | Pharming Group N.V. announced that it expects to receive ?100 million in funding | CI |
| Sales 2024 * | 262M 279M | Sales 2025 * | 300M 320M | Capitalization | 593M 632M |
|---|---|---|---|---|---|
| Net income 2024 * | 1M 1.07M | Net income 2025 * | 14M 14.91M | EV / Sales 2024 * | 1.92 x |
| Net cash position 2024 * | 90.86M 96.79M | Net cash position 2025 * | 119M 127M | EV / Sales 2025 * | 1.58 x |
| P/E ratio 2024 * |
-294
x | P/E ratio 2025 * |
40
x | Employees | 382 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pharming Group N.V.
More recommendations
More press releases
| 1 day | +1.50% | ||
| 1 week | -11.72% | ||
| Current month | -13.54% | ||
| 1 month | -14.47% | ||
| 3 months | -20.77% | ||
| 6 months | -16.73% | ||
| Current year | -14.55% |
1 week
0.86
1.01
1 month
0.861.07
Current year
0.861.22
1 year
0.861.31
3 years
0.661.42
5 years
0.661.64
10 years
0.151.64
| Managers | Title | Age | Since |
|---|---|---|---|
Sijmen de Vries
CEO | Chief Executive Officer | 65 | 08-10-12 |
| Director of Finance/CFO | 55 | 20-11-15 | |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Pykett
BRD | Director/Board Member | 60 | 20-12-10 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 21-05-18 |
Sijmen de Vries
CEO | Chief Executive Officer | 65 | 08-10-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.17% | 2 M€ | -.--% | ||
| 0.05% | 7 M€ | -.--% | - | |
| 0.02% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.881 | +1.50% | 8,926,686 |
| 24-04-18 | 0.868 | -9.63% | 37,599,270 |
| 24-04-17 | 0.9605 | -0.10% | 2,891,437 |
| 24-04-16 | 0.9615 | -2.63% | 6,325,596 |
| 24-04-15 | 0.9875 | -2.23% | 5,323,102 |
Real-time Euronext Amsterdam, April 19, 2024 at 11:35 am EDT
More quotes
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development.
Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.881
EUR
Average target price
2
EUR
Spread / Average Target
+127.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.55% | 623M | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
- Stock Market
- Equities
- PHARM Stock
